ArticleJournal of translational medicine2026
Gene expression profiles in benign prostate tissue reflect tumor proximity, grade, and molecular subtype.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNormal tissue in a tumor-bearing organ shows morphological and molecular differences from normal tissue in a tumor-free organ. One explanation to this is that tumors actively instruct adjacent normal tissues to support growth and invasion. The aim of this study was to examine if changes in gene-expression patterns in tumor-adjacent histologically benign prostate tissue, termed tumor instructed normal tissue (TINT), were associated with tumor proximity, grade and molecular subtype and, furthermore, whether they could indicate the presence of high-grade cancer elsewhere in the prostate.
methodsGene-expression analysis using Clariom D microarrays was performed on matched formalin-fixed paraffin-embedded samples including tumor tissue (n = 44), benign prostate tissue taken near (TINT-N, n = 44) or distant (TINT-D, n = 42) to the tumor in 44 men with unifocal cancer treated by prostatectomy. TINT changes related to cell proliferation and immune cell infiltration were examined using immunohistochemical markers. In addition, gene expression was compared between tumor-negative biopsies from men later diagnosed with high-grade cancer (Bx-later-tumor, n = 46), tumor-negative biopsies from men who remained cancer-free (Bx-control, n = 49), and cancer-containing biopsies (Bx-tumor, n = 28). Gene set enrichment analysis (GSEA) was performed to explore hallmark gene sets in tumor and TINT tissue in relation to tumor grade (high vs. low) and molecular subtype (Luminal B vs. Luminal A).
resultsThe transcriptome in TINT differed significantly from that in cancer-free biopsy control tissue and was related to tumor grade (high- vs. low), molecular subtype (Luminal B vs. Luminal A), and tumor proximity (TINT-N vs. TINT-D). Hallmarks related to cell proliferation and increased Ki67 staining as well as signs of increased metabolism were generally enriched in both tumor and TINT tissue of high grade and Luminal B tumors. In contrast, some immune responses were unique to TINT areas of high-grade and Luminal A tumors, respectively, and more obvious in TINT-N than in TINT-D. Analysis of Bx-later-tumor indicated enriched metabolism compared to Bx-control, without clear proliferative or immunological differences.
conclusionsTINT effects involving proliferation, metabolism and immune responses are related to distance, tumor grade and molecular subtype. TINT alterations hold potential as diagnostic and prognostic biomarkers and may provide a basis for further exploration of tumor-host interactions and potential targets for intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.